Rockville, Md., July 26, 2018 (Business Wire) -
Linical
and
Accelovance
recently
merged
to create a leading midsized, global contract research organization (CRO) with a significant footprint across North America, Europe and Asia-Pacific. As the next step in the merger, Accelovance has incorporated Linical into its name and will operate as Linical Accelovance Group, which includes Linical Accelovance America, Europe, Romania and China. Additionally,
Vita M. Lanoce, M.S
., has been appointed as chief executive officer of Linical Accelovance Group. Lanoce, previously chief operating officer at Accelovance, has more than 22 years of experience in clinical research at companies including Covance, Synexus (formerly Radiant Research) and Bristol-Myers Squibb. In her new role, Lanoce will oversee all business activities for the Linical Accelovance Group. “The name change is the next step for us to work collaboratively under a shared vision of quality, success, innovation and communication,” said Lanoce. “I look forward to ensuring the continued delivery of robust solutions and personal service, and guiding our collective strengths for enhanced service offerings.” Comprising approximately 925 people across more than 20 countries, Linical is the ideal midsized, global CRO partner for drug developers looking to expand their programs into new markets. The company offers the same reach and experience as larger CROs, yet maintains a personalized, hands-on service approach. The new combined company is capable of conducting studies from early-phase research through large-scale, multinational and late-phase trials. As a one-stop provider for clinical development programs, Linical offers a full scope of flexible solutions and a wide range of therapeutic expertise with specializations in dermatology, immunology, neurology, oncology and vaccines. Linical also demonstrates its oncology expertise through its
HERO™ Project
, which combines its scientific expertise and site networks to accelerate oncology therapeutics to market. Additionally, Linical’s patient engagement solutions are clinical research-focused, enhancing patient recruitment, retention, compliance, surveillance and safety data collection.
About Linical
Linical, a global, midsized contract research organization with a significant footprint across North America, Europe and Asia-Pacific, is the ideal partner for drug developers looking to expand their program into new markets. With operations in more than 20 countries, our global reach makes us uniquely capable of conducting large-scale, multinational studies. At Linical, we deliver a personalized, high-touch service approach across a variety of therapeutic areas and in all phases of development. For more information, visitLinical, a global, midsized contract research organization with a significant footprint across North America, Europe and Asia-Pacific, is the ideal partner for drug developers looking to expand their program into new markets. With operations in more than 20 countries, our global reach makes us uniquely capable of conducting large-scale, multinational studies. At Linical, we deliver a personalized, high-touch service approach across a variety of therapeutic areas and in all phases of development. For more information, visit
Linical.cojp/en/
or
Accelovance.com
.
CONTACT:
Alison Cundari Marketing Manager 803.753.4160
acundari@accelovance.com
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.